Balloon predilation or direct valve implantation in TAVI for women: Insights from the DIRECTAVI study.
balloon aortic valvuloplasty
direct TAVI
procedure simplification
transcatheter aortic valve replacement
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
19 May 2024
19 May 2024
Historique:
revised:
05
04
2024
received:
07
12
2023
accepted:
08
05
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
The randomized DIRECTAVI trial demonstrated safety and feasibility of transcatheter aortic valve implantation (TAVI) without balloon aortic valvuloplasty (BAV) using SAPIEN 3 balloon-expandable devices. However, the female population with smaller anatomy may have potential higher risk of residual gradient and/or mismatch. We assessed the impact of BAV on the procedural success rate and clinical outcomes in the female population of the DIRECTAVI trial. Between May 2016 and May 2018, 91 of the 250 patients included in the DIRECTAVI trial were women (38.6%), 45 of them (49.5%) were enrolled in the BAV group and 46 of them (50.5%) in the direct TAVI group. The primary endpoint was procedural success rate in women (Valve Academic Research Consortium-2 criteria). The secondary endpoint included evaluation of PPM and 1-month major adverse events according to the implantation stategy in women and comparison between men and women regarding major endpoints. The primary endpoint occurred in 29 women (64.4%) in the BAV group and in 34 women (73.9%) in the direct TAVI group (mean difference 9.47%; 95% confidence interval: 6.5%-25.4%; p = 0.045 for non-inferiority of the direct strategy). One-month major adverse events were similar between the 2 women groups. Procedural success was lower in women vs men (p = 0.01) due to higher incidence of moderate mismatches in women (p = 0.001) but with no significant difference regarding the implantation strategy (p = 0.4). Direct implantation of the balloon-expandable SAPIEN 3 valve was non-inferior to predilatation on procedural success in women. Incidence of moderate mismatch was higher in women but was not related to the implantation strategy.
Sections du résumé
BACKGROUND
BACKGROUND
The randomized DIRECTAVI trial demonstrated safety and feasibility of transcatheter aortic valve implantation (TAVI) without balloon aortic valvuloplasty (BAV) using SAPIEN 3 balloon-expandable devices. However, the female population with smaller anatomy may have potential higher risk of residual gradient and/or mismatch.
PURPOSE
OBJECTIVE
We assessed the impact of BAV on the procedural success rate and clinical outcomes in the female population of the DIRECTAVI trial.
METHODS
METHODS
Between May 2016 and May 2018, 91 of the 250 patients included in the DIRECTAVI trial were women (38.6%), 45 of them (49.5%) were enrolled in the BAV group and 46 of them (50.5%) in the direct TAVI group. The primary endpoint was procedural success rate in women (Valve Academic Research Consortium-2 criteria). The secondary endpoint included evaluation of PPM and 1-month major adverse events according to the implantation stategy in women and comparison between men and women regarding major endpoints.
RESULTS
RESULTS
The primary endpoint occurred in 29 women (64.4%) in the BAV group and in 34 women (73.9%) in the direct TAVI group (mean difference 9.47%; 95% confidence interval: 6.5%-25.4%; p = 0.045 for non-inferiority of the direct strategy). One-month major adverse events were similar between the 2 women groups. Procedural success was lower in women vs men (p = 0.01) due to higher incidence of moderate mismatches in women (p = 0.001) but with no significant difference regarding the implantation strategy (p = 0.4).
CONCLUSION
CONCLUSIONS
Direct implantation of the balloon-expandable SAPIEN 3 valve was non-inferior to predilatation on procedural success in women. Incidence of moderate mismatch was higher in women but was not related to the implantation strategy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.
Références
Vahanian A, Himbert D. Transcatheter aortic valve implantation. JACC: Cardiovasc Interv. 2011;4(7):758‐759.
Grube E, Naber C, Abizaid A, et al. Feasibility of transcatheter aortic valve implantation without balloon pre‐dilation. JACC: Cardiovasc Interv. 2011;4(7):751‐757.
Toutouzas K, Benetos G, Voudris V, et al. Pre‐dilatation versus no pre‐dilatation for implantation of a self‐expanding valve in all comers undergoing TAVR. JACC: Cardiovasc Interv. 2019;12(8):767‐777.
Leclercq F, Robert P, Akodad M, et al. Prior balloon valvuloplasty versus direct transcatheter aortic valve replacement. JACC: Cardiovasc Interv. 2020;13(5):594‐602.
Möllmann H, Kim WK, Kempfert J, et al. Transfemoral aortic valve implantation of EdwardsSAPIEN XT without predilatation is feasible. Clin Cardiol. 2014;37(11):667‐671.
Eltchantnoff H, Cribier A, Tron C, et al. Balloon aortic valvuloplasty in elderly patients at high risk for surgery, or inoperable. Eur Heart J. 1995;16(8):1079‐1084.
Sack S, Kahlert P, Khandanpour S, et al. Revival of an old method with new techniques: balloon aortic valvuloplasty of the calcified aortic stenosis in the elderly. Clin Res Cardiol. 2008;97(5):288‐297.
Williams M, Kodali SK, Hahn RT, et al. Sex‐related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis. J Am Coll Cardiol. 2014;63(15):1522‐1528.
Skelding KA, Yakubov SJ, Kleiman NS, et al. Transcatheter aortic valve replacement versus surgery in women at high risk for surgical aortic valve replacement (from the CoreValve US High Risk Pivotal Trial). Am J Cardiol. 2016;118(4):560‐566.
Panoulas VF, Francis DP, Ruparelia N, et al. Female‐specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: meta‐analysis of the gender subgroups of randomised controlled trials including 3758 patients. Int J Cardiol. 2018;250:66‐72.
Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence and sequelae of prosthesis‐patient mismatch in transcatheter versus surgical valve replacement in high‐risk patients with severe aortic stenosis. J Am Coll Cardiol. 2014;64(13):1323‐1334.
Leclercq F, Robert P, Labour J, et al. Prior balloon valvuloplasty versus DIRECT transcatheter aortic valve implantation (DIRECTAVI): study protocol for a randomized controlled trial. Trials. 2017;18(1):303.
Du Cailar C, Gandet T, Du Cailar M, Albat B. A simple sheath removal after open trans‐femoral catheterization procedure: the ZIP technique. Eur J Cardiothorac Surg. 2014;45(4):746‐748.
Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium‐2 consensus document (VARC‐2). Eur J Cardiothorac Surg. 2012;42(5):S45‐S60.
Deharo P, Jaussaud N, Grisoli D, et al. Impact of direct transcatheter aortic valve replacement without balloon aortic valvuloplasty on procedural and clinical outcomes. JACC: Cardiovasc Interv. 2018;11(19):1956‐1965.
Fiorina C, Maffeo D, Curello S, et al. Direct transcatheter aortic valve implantation with self‐expandable bioprosthesis: feasibility and safety. Cardiovasc Revasc Med. 2014;15(4):200‐203.
Auffret V, Regueiro A, Campelo‐Parada F, et al. Feasibility, safety, and efficacy of transcatheter aortic valve replacement without balloon predilation: a systematic review and meta‐analysis. Catheter Cardiovasc Interv. 2017;90(5):839‐850.
Liao Y, Meng Y, Zhao Z, et al. Meta‐analysis of the effectiveness and safety of transcatheter aortic valve implantation without balloon predilation. Am J Cardiol. 2016;117(10):1629‐1635.
Patsalis PC, Al‐Rashid F, Neumann T, et al. Preparatory balloon aortic valvuloplasty during transcatheter aortic valve implantation for improved valve sizing. JACC: Cardiovasc Interv. 2013;6(9):965‐971.
Chieffo A, Petronio AS, Mehilli J, et al. 1‐Year clinical outcomes in women after transcatheter aortic valve replacement. JACC: Cardiovasc Interv. 2018;11(1):1‐12.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic‐valve replacement with a balloon‐expandable valve in low‐risk patients. N Engl J Med. 2019;380(18):1695‐1705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic‐valve replacement with a self‐expanding valve in low‐risk patients. N Engl J Med. 2019;380(18):1706‐1715.
Auffret V, Lefevre T, Van Belle E, et al. Temporal trends in transcatheter aortic valve replacement in France. J Am Coll Cardiol. 2017;70(1):42‐55.
Chan PH, Mario CD, Moat N. Transcatheter aortic valve implantation without balloon predilatation: not always feasible. Catheter Cardiovasc Interv. 2013;82(2):328‐332.
Tchetche D. Do we need any new TAVR device? Lancet. 2019;394(10209):1593‐1594.